Form 4: Artivion SVP, Clinical & MD Affairs, Marshall S. Stanton, Reports Stock Transactions

Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc., reports acquisition of 5,724 shares and disposition of 1,506 shares of common stock.

Summary

• On March 1, 2024, Marshall S. Stanton acquired 5,724 shares of Artivion, Inc. common stock.
• These shares were LTIP performance stock units.
• On March 5, 2024, Stanton disposed of 1,506 shares at a price of $18.7221 per share.
• The sale was to cover tax withholding obligations related to the vesting of performance stock units.
• Following these transactions, Stanton beneficially owns 85,438 shares of Artivion, Inc. common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions appear routine and related to compensation and tax obligations. The acquisition is a positive sign, but the sale offsets some of that.

Positives

• The acquisition of 5,724 shares indicates confidence in the company's performance.

Negatives

• The sale of 1,506 shares, while for tax obligations, could be perceived negatively by some investors.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects.

Stakeholder Impact

• Shareholders may be interested in executive stock transactions as an indicator of management's confidence in the company.
• Employees participating in similar LTIP programs will be interested in the vesting and tax implications.

Key Dates